News Releases

RNS Number : 3392P MaxCyte, Inc. 17 June 2022   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing

RNS Number : 6936N MaxCyte, Inc. 06 June 2022       Publication of Annual Report   GAITHERSBURG, MD , June 6, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research

RNS Number : 0074N MaxCyte, Inc. 27 May 2022       Notice of AGM   GAITHERSBURG, MD , May 27, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as

RNS Number : 5037L MaxCyte, Inc. 16 May 2022   MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , May 16, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 8601K MaxCyte, Inc. 10 May 2022           MaxCyte Reports First Quarter Financial Results   MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million   GAITHERSBURG, MD , May 10, 2022   - MaxCyte, Inc.

RNS Number : 9104K MaxCyte, Inc. 10 May 2022       MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2022   GAITHERSBURG, MD , May 10, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading   commercial cell engineering company focused on providing enabling

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling

RNS Number : 1970K MaxCyte, Inc. 04 May 2022   MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , May 4, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance

GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,